Want to see QSI full AI Analyst Report?
Top Page
Quantum-Si
(NASDAQ:QSI)
Select Model
Select Model
Rating:56Neutral
Price Target:
$1.50
▲(89.87% Upside)
Action:Reiterated
Date:10/28/26
The score reflects a high-risk fundamental backdrop—minimal and declining revenue, persistent large losses, and continued cash burn—partly mitigated by low leverage and an extended cash runway following planned cost actions. Technicals are currently the strongest pillar (price above major moving averages with positive MACD), while valuation support is limited due to negative earnings and no dividend. Earnings-call messaging was balanced: clearer runway and discipline, but a meaningful Proteus delay and sharp revenue declines weigh on near-term confidence.
Positive Factors
Extended Cash Runway
The sizable cash position and planned expense reductions give Quantum-Si time to fund Proteus development and commercial preparation without immediate balance-sheet pressure. A runway extending into Q4 2028 also provides flexibility to execute the revised launch plan while pursuing operating discipline.
Negative Factors
Sharp Revenue Contraction
The steep revenue decline shows that Quantum-Si has not yet established consistent commercial scale, leaving current sales far below the expense base. Continued weak demand or delayed capital purchases could limit customer adoption, reduce operating leverage, and prolong dependence on external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended Cash Runway
The sizable cash position and planned expense reductions give Quantum-Si time to fund Proteus development and commercial preparation without immediate balance-sheet pressure. A runway extending into Q4 2028 also provides flexibility to execute the revised launch plan while pursuing operating discipline.
Read all positive factors
Quantum-Si Key Performance Indicators (KPIs)
Any
Revenue by Segment
Details revenue contributions from each business unit, highlighting which areas are most lucrative and where growth or decline is occurring.
Details revenue contributions from each business unit, highlighting which areas are most lucrative and where growth or decline is occurring.
Data provided by:
The Fly
The FlyQuantum-Si (QSI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$361.16M
Dividend YieldN/A
Average Volume (3M)8.72M
Price to Earnings (P/E)―
Beta (1Y)3.22
Revenue Growth-52.96%
EPS Growth30.51%
CountryUS
Employees145
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.46
Shares Outstanding198,946,410
10 Day Avg. Volume7,202,497
30 Day Avg. Volume8,720,177
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.99
Price to Sales (P/S)89.30
P/FCF Ratio-2.24
Enterprise Value/Market Cap0.23
Enterprise Value/Revenue52.50
Enterprise Value/Gross Profit149.94
Enterprise Value/Ebitda-0.93
Forecast
1Y Price Target
$2.95Price Target Upside273.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.43
Revenue Forecast (FY)$1.15M
Quantum-Si Business Overview & Revenue Model
Company Description
Quantum-Si incorporated operates within the life sciences sector, focusing on the creation of an advanced platform for individual molecule detection. This innovative technology is designed to streamline sample preparation and subsequent sequencing...
Quantum-Si Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Neutral
The call conveyed a balanced message: positive technical progress, strengthened commercial insights and a clarified plan to preserve cash and extend runway into Q4 2028, but offset by a meaningful delay to Proteus launch, significant year-over-year revenue declines, a ~20% workforce reduction and continued operating losses. Management framed the delay as a responsible decision to de-risk launch and emphasized cost actions and market preparation, while acknowledging near-term headwinds to revenue and timing of customer access.Positive Updates
Proteus technical confidence despite timeline revision
Management reiterated strong confidence in Proteus underlying technology based on sequencing data from integrated units; added an additional integrated instrument design cycle to derisk manufacturing and improve repeatability prior to production.
Negative Updates
Proteus launch delayed to Q2 2027
Launch timeline moved from end of 2026 to second quarter 2027 to add another integrated instrument design cycle and strengthen program governance — early access and field deployments will shift later into 2027.
Read all updates
Q2-2026 Updates
Positive
Negative
Proteus technical confidence despite timeline revision
Management reiterated strong confidence in Proteus underlying technology based on sequencing data from integrated units; added an additional integrated instrument design cycle to derisk manufacturing and improve repeatability prior to production.
Read all positive updates
Company Guidance
Management reiterated full‑year 2026 guidance of approximately $1.0 million in revenue, adjusted operating expenses of $98 million or less, and total cash usage of $93 million or less; they expect ~ $12 million of annual OpEx savings from a targeted ~20% headcount reduction and said the actions, together with $169.9 million in cash, cash equivalents and marketable securities as of June 30, 2026, support operations into Q4 2028 while funding the revised Proteus plan (targeting a Q2 2027 launch). Key reported results underpinning that guidance included Q2 revenue $344k (H1 $602k), Q2 gross profit $172k (gross margin 50%; H1 gross profit $246k, margin 41%), Q2 GAAP operating expenses $25.8M (adjusted $22.6M; H1 GAAP $49.9M, adjusted $43.9M), Q2 net loss $23.5M (adjusted EBITDA -$21.2M), and dividend & interest income of $1.7M in Q2.Quantum-Si Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.60M | 2.44M | 3.06M | 1.08M | 0.00 | 0.00 |
| Gross Profit | 562.00K | 1.15M | 1.60M | 488.00K | 0.00 | 0.00 |
| EBITDA | -90.81M | -92.91M | -96.35M | -91.80M | -111.77M | -93.94M |
| Net Income | -98.52M | -101.34M | -101.01M | -95.96M | -132.44M | -94.99M |
Balance Sheet | ||||||
| Total Assets | 193.57M | 245.61M | 247.87M | 298.25M | 391.49M | 503.23M |
| Cash, Cash Equivalents and Short-Term Investments | 111.74M | 162.91M | 209.60M | 257.74M | 351.31M | 471.30M |
| Total Debt | 3.25M | 4.17M | 12.95M | 15.30M | 17.45M | 8.08M |
| Total Liabilities | 13.37M | 25.38M | 32.45M | 26.63M | 32.78M | 26.19M |
| Stockholders Equity | 180.20M | 220.23M | 215.42M | 271.62M | 358.71M | 477.03M |
Cash Flow | ||||||
| Free Cash Flow | -93.69M | -97.23M | -92.38M | -99.31M | -101.30M | -72.58M |
| Operating Cash Flow | -92.45M | -94.72M | -87.80M | -94.04M | -90.56M | -66.81M |
| Investing Cash Flow | 49.21M | -28.32M | -32.67M | 143.43M | 137.19M | -450.94M |
| Financing Cash Flow | 47.01M | 95.42M | 35.88M | 149.00K | 1.91M | 516.63M |
Quantum-Si Technical Analysis
Positive
0.79
Price Trends
0.99
Positive
0.92
Positive
0.96
Positive
Market Momentum
0.12
Negative
66.65
Neutral
89.63
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Positive. The current price of 0.79 is below the 20-day moving average (MA) of 1.32, below the 50-day MA of 0.99, and below the 200-day MA of 0.96, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 66.65 is Neutral, neither overbought nor oversold. The STOCH value of 89.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QSI.
Quantum-Si Risk Analysis
Quantum-Si disclosed 69 risk factors in its most recent earnings report. Quantum-Si reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quantum-Si Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $10.18B | 45.74 | 3.15% | ― | 1.37% | -29.25% | |
59 Neutral | $9.25B | -86.90 | -2.92% | 0.33% | 1.65% | -233.85% | |
57 Neutral | $777.30M | -9.60 | -23.53% | ― | 5.44% | -1130.00% | |
56 Neutral | $361.16M | -3.55 | -47.12% | ― | -52.96% | 30.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $761.54M | -5.70 | -4961.74% | ― | 2.02% | 75.85% | |
48 Neutral | $136.68M | -1.10 | -43.59% | ― | 21.96% | -44.65% |
* Healthcare Sector Average
QSI
Quantum-Si
1.65
-0.53
-24.31%
BIO
Bio-Rad Laboratories
380.99
50.57
15.30%
BRKR
Bruker
60.74
22.18
57.54%
PACB
Pacific Biosciences
2.45
0.48
24.37%
QTRX
Quanterix
2.89
-2.59
-47.26%
CTKB
Cytek Biosciences
5.98
1.78
42.38%
Quantum-Si Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Quantum-Si Regains Nasdaq Compliance After Bid Price Recovery
Positive
Oct 15, 2026
On July 23, 2026, Quantum-Si received notice from Nasdaq that its Class A common stock had closed below $1.00 per share for 30 consecutive business days, putting the company out of compliance with the Global Market’s minimum bid price requir...
Business Operations and StrategyProduct-Related Announcements
Quantum-Si advances Proteus platform with 19-amino-acid detection
Positive
Oct 8, 2026
On October 8, 2026, Quantum-Si announced it had demonstrated detection of 19 amino acids in its Proteus development program, advancing beyond earlier interim results shown at the 2026 World HUPO Congress. The company is now working to integrate th...
Business Operations and StrategyProduct-Related Announcements
Quantum-Si Showcases Proteus Platform Advancements at World HUPO
Positive
Sep 29, 2026
On September 28, 2026, Quantum-Si published a presentation for investors and scientific audiences tied to its World HUPO 2026 appearance in Singapore, detailing interim development data for its Proteus single-molecule protein sequencing platform. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.